TABLE 2.

Adverse events.

	Placebo (n = 7)	50 mg (n = 3)	100 mg (n = 6)	200 mg (n = 6)	400 mg (n = 6)	All SHR2285 (n = 21)
Adverse events of any cause, n (%)	3 (42.9)	1 (33.3)	3 (50.0)	4 (66.7)	4 (66.7)	12 (57.1)
Biological
Blood triglycerides increased	2 (28.6)	0	0	0	0	0
White blood cell count decreased	0	0	1 (16.7)	0	0	1 (4.8)
Bilirubin conjugated increased	0	0	2 (33.3)	0	2 (33.3)	4 (19.0)
Occult blood positive	0	0	0	3 (50.0)	1 (16.7)	4 (19.0)
Blood bilirubin increased	0	0	1 (16.7)	0	2 (33.3)	3 (14.3)
Blood alkaline phosphatase increased	0	0	0	0	1 (16.7)	1 (4.8)
Neutrophil count decreased	0	0	2 (33.3)	1 (16.7)	0	3 (14.3)
Clinical
Pain in jaw	0	0	0	0	1 (16.7)	1 (4.8)
Oropharyngeal pain	0	0	0	0	1 (16.7)	1 (4.8)
Abdominal discomfort	0	0	0	0	1 (16.7)	1 (4.8)
Diarrhea	0	0	0	1 (16.7)	0	1 (4.8)
Ventricular extrasystoles	0	1 (33.3)	0	0	0	1 (4.8)
Productive cough	0	0	1 (16.7)	0	0	1 (4.8)
Musculoskeletal discomfort	1 (14.3)	0	0	0	0	0
Treatment-related adverse events, n(%)	2 (28.6)	0	2 (33.3)	4 (66.7)	5 (83.3)	11 (52.4)
Biological
Blood triglycerides increased	2 (28.6)	0	0	0	0	0
White blood cell count decreased	0	0	1 (16.7)	0	0	1 (4.8)
Bilirubin conjugated increased	0	0	2 (33.3)	0	2 (33.3)	4 (19.0)
Occult blood positive	0	0	0	3 (50.0)	1 (16.7)	4 (19.0)
Blood bilirubin increased	0	0	1 (16.7)	0	2 (33.3)	3 (14.3)
Blood alkaline phosphatase increased	0	0	0	0	1 (16.7)	1 (4.8)
Neutrophil count decreased	0	0	2 (33.3)	1 (16.7)	0	3 (14.3)

Data are n (%). “Treatment-related” is defined as the relationship of an adverse event to the study drug being certain, probable, or possible.